CD138 (syndecan-1) expression in bone-forming tumors

Area of Science:

• Oncology
• Pathology
• Biomarker Research

Background:

• CD138 (syndecan-1) is a cell surface proteoglycan crucial for identifying plasmacytic differentiation in hematologic disorders.
• While CD138 expression is noted in epithelial and soft tissue neoplasms, its role in bone tumors remains largely unevaluated.

Purpose of the Study:

• To investigate CD138 expression in various primary bone tumors and reactive bone lesions.
• To determine if CD138 can serve as a specific marker for plasmacytic differentiation in bone neoplasms.

Main Methods:

• CD138 expression was assessed immunohistochemically in 27 osteosarcomas, 12 benign bone-forming tumors, and 17 reactive bone cases.
• A tissue microarray (TMA) of 24 osteosarcomas, 24 chondrosarcomas, 12 giant cell tumors, and 9 normal bone samples was also analyzed for CD138.
• Immunoglobulin kappa and lambda stains were performed on CD138-positive cases.

Main Results:

• CD138 was expressed in 52% of in-house osteosarcoma cases and 8% of TMA osteosarcoma cases, and in 83% of osteoid osteoma/osteoblastoma cases.
• No CD138 reactivity was observed in chondrosarcomas, giant cell tumors of bone, or normal/reactive bone samples.
• Immunoglobulin stains were negative in all CD138-positive bone tumor cases, ruling out plasmacytic origin.

Conclusions:

• CD138 expression in bone tumors does not reliably indicate plasmacytic differentiation.
• Caution is advised when interpreting CD138-positive cells in bony lesions without established hematologic etiology.
• CD138 is not a definitive marker for plasma cell neoplasms in bone.